Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Identifieur interne : 000290 ( PubMed/Curation ); précédent : 000289; suivant : 000291Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Auteurs : Robert P. Giugliano [États-Unis] ; Terje R. Pedersen [Norvège] ; Jeong-Gun Park [États-Unis] ; Gaetano M. De Ferrari [Italie] ; Zbigniew A. Gaciong [Pologne] ; Richard Ceska [République tchèque] ; Kalman Toth [Hongrie] ; Ioanna Gouni-Berthold [Allemagne] ; Jose Lopez-Miranda [Espagne] ; François Schiele [France] ; François Mach [Suisse] ; Brian R. Ott [États-Unis] ; Estella Kanevsky [États-Unis] ; Armando Lira Pineda [États-Unis] ; Ransi Somaratne [États-Unis] ; Scott M. Wasserman [États-Unis] ; Anthony C. Keech [Australie] ; Peter S. Sever [Royaume-Uni] ; Marc S. Sabatine [États-Unis]Source :
- Lancet (London, England) [ 1474-547X ] ; 2017.
Abstract
LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between progressively lower LDL-cholesterol concentrations achieved at 4 weeks and clinical efficacy and safety in the FOURIER trial of evolocumab, a monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9).
DOI: 10.1016/S0140-6736(17)32290-0
PubMed: 28859947
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000292
Links to Exploration step
pubmed:28859947Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.</title><author><name sortKey="Giugliano, Robert P" sort="Giugliano, Robert P" uniqKey="Giugliano R" first="Robert P" last="Giugliano">Robert P. Giugliano</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: rgiugliano@bwh.harvard.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Pedersen, Terje R" sort="Pedersen, Terje R" uniqKey="Pedersen T" first="Terje R" last="Pedersen">Terje R. Pedersen</name><affiliation wicri:level="1"><nlm:affiliation>Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo</wicri:regionArea></affiliation></author><author><name sortKey="Park, Jeong Gun" sort="Park, Jeong Gun" uniqKey="Park J" first="Jeong-Gun" last="Park">Jeong-Gun Park</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="De Ferrari, Gaetano M" sort="De Ferrari, Gaetano M" uniqKey="De Ferrari G" first="Gaetano M" last="De Ferrari">Gaetano M. De Ferrari</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Medicine, University of Pavia and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Molecular Medicine, University of Pavia and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia</wicri:regionArea></affiliation></author><author><name sortKey="Gaciong, Zbigniew A" sort="Gaciong, Zbigniew A" uniqKey="Gaciong Z" first="Zbigniew A" last="Gaciong">Zbigniew A. Gaciong</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw, Warsaw</wicri:regionArea></affiliation></author><author><name sortKey="Ceska, Richard" sort="Ceska, Richard" uniqKey="Ceska R" first="Richard" last="Ceska">Richard Ceska</name><affiliation wicri:level="1"><nlm:affiliation>Center of Preventive Cardiology, 3rd Department Internal Medicine, University General Hospital and 1st Medical Faculty, Prague, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Center of Preventive Cardiology, 3rd Department Internal Medicine, University General Hospital and 1st Medical Faculty, Prague</wicri:regionArea></affiliation></author><author><name sortKey="Toth, Kalman" sort="Toth, Kalman" uniqKey="Toth K" first="Kalman" last="Toth">Kalman Toth</name><affiliation wicri:level="1"><nlm:affiliation>1st Department of Medicine, University of Pécs, Pécs, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>1st Department of Medicine, University of Pécs, Pécs</wicri:regionArea></affiliation></author><author><name sortKey="Gouni Berthold, Ioanna" sort="Gouni Berthold, Ioanna" uniqKey="Gouni Berthold I" first="Ioanna" last="Gouni-Berthold">Ioanna Gouni-Berthold</name><affiliation wicri:level="1"><nlm:affiliation>Polyclinic for Endocrinology, Diabetes, and Preventive Medicine, University of Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Polyclinic for Endocrinology, Diabetes, and Preventive Medicine, University of Cologne, Cologne</wicri:regionArea></affiliation></author><author><name sortKey="Lopez Miranda, Jose" sort="Lopez Miranda, Jose" uniqKey="Lopez Miranda J" first="Jose" last="Lopez-Miranda">Jose Lopez-Miranda</name><affiliation wicri:level="1"><nlm:affiliation>Lipids and Atherosclerosis Unit, Maimonides Biomedical Research Institute of Cordoba, Reina Sofia University Hospital, University of Cordoba, CIBEROBN, Cordoba, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Lipids and Atherosclerosis Unit, Maimonides Biomedical Research Institute of Cordoba, Reina Sofia University Hospital, University of Cordoba, CIBEROBN, Cordoba</wicri:regionArea></affiliation></author><author><name sortKey="Schiele, Francois" sort="Schiele, Francois" uniqKey="Schiele F" first="François" last="Schiele">François Schiele</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Center Besançon, Besançon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Hospital Center Besançon, Besançon</wicri:regionArea></affiliation></author><author><name sortKey="Mach, Francois" sort="Mach, Francois" uniqKey="Mach F" first="François" last="Mach">François Mach</name><affiliation wicri:level="1"><nlm:affiliation>Hopital Cantonal, Hopitaux Universitaires de Geneva, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Hopital Cantonal, Hopitaux Universitaires de Geneva, Geneva</wicri:regionArea></affiliation></author><author><name sortKey="Ott, Brian R" sort="Ott, Brian R" uniqKey="Ott B" first="Brian R" last="Ott">Brian R. Ott</name><affiliation wicri:level="1"><nlm:affiliation>Rhode Island Hospital, Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Rhode Island Hospital, Department of Neurology, Alpert Medical School of Brown University, Providence, RI</wicri:regionArea></affiliation></author><author><name sortKey="Kanevsky, Estella" sort="Kanevsky, Estella" uniqKey="Kanevsky E" first="Estella" last="Kanevsky">Estella Kanevsky</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Pineda, Armando Lira" sort="Pineda, Armando Lira" uniqKey="Pineda A" first="Armando Lira" last="Pineda">Armando Lira Pineda</name><affiliation wicri:level="1"><nlm:affiliation>Amgen, Thousand Oaks, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen, Thousand Oaks, CA</wicri:regionArea></affiliation></author><author><name sortKey="Somaratne, Ransi" sort="Somaratne, Ransi" uniqKey="Somaratne R" first="Ransi" last="Somaratne">Ransi Somaratne</name><affiliation wicri:level="1"><nlm:affiliation>Amgen, Thousand Oaks, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen, Thousand Oaks, CA</wicri:regionArea></affiliation></author><author><name sortKey="Wasserman, Scott M" sort="Wasserman, Scott M" uniqKey="Wasserman S" first="Scott M" last="Wasserman">Scott M. Wasserman</name><affiliation wicri:level="1"><nlm:affiliation>Amgen, Thousand Oaks, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen, Thousand Oaks, CA</wicri:regionArea></affiliation></author><author><name sortKey="Keech, Anthony C" sort="Keech, Anthony C" uniqKey="Keech A" first="Anthony C" last="Keech">Anthony C. Keech</name><affiliation wicri:level="1"><nlm:affiliation>Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW</wicri:regionArea></affiliation></author><author><name sortKey="Sever, Peter S" sort="Sever, Peter S" uniqKey="Sever P" first="Peter S" last="Sever">Peter S. Sever</name><affiliation wicri:level="1"><nlm:affiliation>International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Sabatine, Marc S" sort="Sabatine, Marc S" uniqKey="Sabatine M" first="Marc S" last="Sabatine">Marc S. Sabatine</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28859947</idno><idno type="pmid">28859947</idno><idno type="doi">10.1016/S0140-6736(17)32290-0</idno><idno type="wicri:Area/PubMed/Corpus">000292</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000292</idno><idno type="wicri:Area/PubMed/Curation">000290</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000290</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.</title><author><name sortKey="Giugliano, Robert P" sort="Giugliano, Robert P" uniqKey="Giugliano R" first="Robert P" last="Giugliano">Robert P. Giugliano</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: rgiugliano@bwh.harvard.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Pedersen, Terje R" sort="Pedersen, Terje R" uniqKey="Pedersen T" first="Terje R" last="Pedersen">Terje R. Pedersen</name><affiliation wicri:level="1"><nlm:affiliation>Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo</wicri:regionArea></affiliation></author><author><name sortKey="Park, Jeong Gun" sort="Park, Jeong Gun" uniqKey="Park J" first="Jeong-Gun" last="Park">Jeong-Gun Park</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="De Ferrari, Gaetano M" sort="De Ferrari, Gaetano M" uniqKey="De Ferrari G" first="Gaetano M" last="De Ferrari">Gaetano M. De Ferrari</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Medicine, University of Pavia and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Molecular Medicine, University of Pavia and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia</wicri:regionArea></affiliation></author><author><name sortKey="Gaciong, Zbigniew A" sort="Gaciong, Zbigniew A" uniqKey="Gaciong Z" first="Zbigniew A" last="Gaciong">Zbigniew A. Gaciong</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw, Warsaw</wicri:regionArea></affiliation></author><author><name sortKey="Ceska, Richard" sort="Ceska, Richard" uniqKey="Ceska R" first="Richard" last="Ceska">Richard Ceska</name><affiliation wicri:level="1"><nlm:affiliation>Center of Preventive Cardiology, 3rd Department Internal Medicine, University General Hospital and 1st Medical Faculty, Prague, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Center of Preventive Cardiology, 3rd Department Internal Medicine, University General Hospital and 1st Medical Faculty, Prague</wicri:regionArea></affiliation></author><author><name sortKey="Toth, Kalman" sort="Toth, Kalman" uniqKey="Toth K" first="Kalman" last="Toth">Kalman Toth</name><affiliation wicri:level="1"><nlm:affiliation>1st Department of Medicine, University of Pécs, Pécs, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>1st Department of Medicine, University of Pécs, Pécs</wicri:regionArea></affiliation></author><author><name sortKey="Gouni Berthold, Ioanna" sort="Gouni Berthold, Ioanna" uniqKey="Gouni Berthold I" first="Ioanna" last="Gouni-Berthold">Ioanna Gouni-Berthold</name><affiliation wicri:level="1"><nlm:affiliation>Polyclinic for Endocrinology, Diabetes, and Preventive Medicine, University of Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Polyclinic for Endocrinology, Diabetes, and Preventive Medicine, University of Cologne, Cologne</wicri:regionArea></affiliation></author><author><name sortKey="Lopez Miranda, Jose" sort="Lopez Miranda, Jose" uniqKey="Lopez Miranda J" first="Jose" last="Lopez-Miranda">Jose Lopez-Miranda</name><affiliation wicri:level="1"><nlm:affiliation>Lipids and Atherosclerosis Unit, Maimonides Biomedical Research Institute of Cordoba, Reina Sofia University Hospital, University of Cordoba, CIBEROBN, Cordoba, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Lipids and Atherosclerosis Unit, Maimonides Biomedical Research Institute of Cordoba, Reina Sofia University Hospital, University of Cordoba, CIBEROBN, Cordoba</wicri:regionArea></affiliation></author><author><name sortKey="Schiele, Francois" sort="Schiele, Francois" uniqKey="Schiele F" first="François" last="Schiele">François Schiele</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Center Besançon, Besançon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Hospital Center Besançon, Besançon</wicri:regionArea></affiliation></author><author><name sortKey="Mach, Francois" sort="Mach, Francois" uniqKey="Mach F" first="François" last="Mach">François Mach</name><affiliation wicri:level="1"><nlm:affiliation>Hopital Cantonal, Hopitaux Universitaires de Geneva, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Hopital Cantonal, Hopitaux Universitaires de Geneva, Geneva</wicri:regionArea></affiliation></author><author><name sortKey="Ott, Brian R" sort="Ott, Brian R" uniqKey="Ott B" first="Brian R" last="Ott">Brian R. Ott</name><affiliation wicri:level="1"><nlm:affiliation>Rhode Island Hospital, Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Rhode Island Hospital, Department of Neurology, Alpert Medical School of Brown University, Providence, RI</wicri:regionArea></affiliation></author><author><name sortKey="Kanevsky, Estella" sort="Kanevsky, Estella" uniqKey="Kanevsky E" first="Estella" last="Kanevsky">Estella Kanevsky</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Pineda, Armando Lira" sort="Pineda, Armando Lira" uniqKey="Pineda A" first="Armando Lira" last="Pineda">Armando Lira Pineda</name><affiliation wicri:level="1"><nlm:affiliation>Amgen, Thousand Oaks, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen, Thousand Oaks, CA</wicri:regionArea></affiliation></author><author><name sortKey="Somaratne, Ransi" sort="Somaratne, Ransi" uniqKey="Somaratne R" first="Ransi" last="Somaratne">Ransi Somaratne</name><affiliation wicri:level="1"><nlm:affiliation>Amgen, Thousand Oaks, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen, Thousand Oaks, CA</wicri:regionArea></affiliation></author><author><name sortKey="Wasserman, Scott M" sort="Wasserman, Scott M" uniqKey="Wasserman S" first="Scott M" last="Wasserman">Scott M. Wasserman</name><affiliation wicri:level="1"><nlm:affiliation>Amgen, Thousand Oaks, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen, Thousand Oaks, CA</wicri:regionArea></affiliation></author><author><name sortKey="Keech, Anthony C" sort="Keech, Anthony C" uniqKey="Keech A" first="Anthony C" last="Keech">Anthony C. Keech</name><affiliation wicri:level="1"><nlm:affiliation>Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW</wicri:regionArea></affiliation></author><author><name sortKey="Sever, Peter S" sort="Sever, Peter S" uniqKey="Sever P" first="Peter S" last="Sever">Peter S. Sever</name><affiliation wicri:level="1"><nlm:affiliation>International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Sabatine, Marc S" sort="Sabatine, Marc S" uniqKey="Sabatine M" first="Marc S" last="Sabatine">Marc S. Sabatine</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA</wicri:regionArea></affiliation></author></analytic><series><title level="j">Lancet (London, England)</title><idno type="eISSN">1474-547X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between progressively lower LDL-cholesterol concentrations achieved at 4 weeks and clinical efficacy and safety in the FOURIER trial of evolocumab, a monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9).</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">28859947</PMID><DateCreated><Year>2017</Year><Month>09</Month><Day>01</Day></DateCreated><DateRevised><Year>2017</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>390</Volume><Issue>10106</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.</ArticleTitle><Pagination><MedlinePgn>1962-1971</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(17)32290-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(17)32290-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between progressively lower LDL-cholesterol concentrations achieved at 4 weeks and clinical efficacy and safety in the FOURIER trial of evolocumab, a monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this prespecified secondary analysis of 25 982 patients from the randomised FOURIER trial, the relationship between achieved LDL-cholesterol concentration at 4 weeks and subsequent cardiovascular outcomes (primary endpoint was the composite of cardiovascular death, myocardial infarction, stroke, coronary revascularisation, or unstable angina; key secondary endpoint was the composite of cardiovascular death, myocardial infarction, or stroke) and ten prespecified safety events of interest was examined over a median of 2·2 years of follow-up. We used multivariable modelling to adjust for baseline factors associated with achieved LDL cholesterol. This trial is registered with ClinicalTrials.gov, number NCT01764633.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between Feb 8, 2013, and June 5, 2015, 27 564 patients were randomly assigned a treatment in the FOURIER study. 1025 (4%) patients did not have an LDL cholesterol measured at 4 weeks and 557 (2%) had already had a primary endpoint event or one of the ten prespecified safety events before the week-4 visit. From the remaining 25 982 patients (94% of those randomly assigned) 13 013 were assigned evolocumab and 12 969 were assigned placebo. 2669 (10%) of 25 982 patients achieved LDL-cholesterol concentrations of less than 0·5 mmol/L, 8003 (31%) patients achieved concentrations between 0·5 and less than 1·3 mmol/L, 3444 (13%) patients achieved concentrations between 1·3 and less than 1·8 mmol/L, 7471 (29%) patients achieved concentrations between 1·8 to less than 2·6 mmol/L, and 4395 (17%) patients achieved concentrations of 2·6 mmol/L or higher. There was a highly significant monotonic relationship between low LDL-cholesterol concentrations and lower risk of the primary and secondary efficacy composite endpoints extending to the bottom first percentile (LDL-cholesterol concentrations of less than 0·2 mmol/L; p=0·0012 for the primary endpoint, p=0·0001 for the secondary endpoint). Conversely, no significant association was observed between achieved LDL cholesterol and safety outcomes, either for all serious adverse events or any of the other nine prespecified safety events.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">There was a monotonic relationship between achieved LDL cholesterol and major cardiovascular outcomes down to LDL-cholesterol concentrations of less than 0·2 mmol/L. Conversely, there were no safety concerns with very low LDL-cholesterol concentrations over a median of 2·2 years. These data support further LDL-cholesterol lowering in patients with cardiovascular disease to well below current recommendations.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Amgen.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giugliano</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: rgiugliano@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Terje R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jeong-Gun</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Ferrari</LastName><ForeName>Gaetano M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, University of Pavia and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaciong</LastName><ForeName>Zbigniew A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceska</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center of Preventive Cardiology, 3rd Department Internal Medicine, University General Hospital and 1st Medical Faculty, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toth</LastName><ForeName>Kalman</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1st Department of Medicine, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouni-Berthold</LastName><ForeName>Ioanna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Polyclinic for Endocrinology, Diabetes, and Preventive Medicine, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez-Miranda</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Lipids and Atherosclerosis Unit, Maimonides Biomedical Research Institute of Cordoba, Reina Sofia University Hospital, University of Cordoba, CIBEROBN, Cordoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiele</LastName><ForeName>François</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University Hospital Center Besançon, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>François</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hopital Cantonal, Hopitaux Universitaires de Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Rhode Island Hospital, Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanevsky</LastName><ForeName>Estella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pineda</LastName><ForeName>Armando Lira</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Amgen, Thousand Oaks, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Somaratne</LastName><ForeName>Ransi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Amgen, Thousand Oaks, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wasserman</LastName><ForeName>Scott M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Amgen, Thousand Oaks, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keech</LastName><ForeName>Anthony C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sever</LastName><ForeName>Peter S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabatine</LastName><ForeName>Marc S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>FOURIER Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>08</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>08</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28859947</ArticleId><ArticleId IdType="pii">S0140-6736(17)32290-0</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(17)32290-0</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000290 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000290 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28859947
|texte= Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28859947" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |